Search for: All records

The coronavirus disease 2019 (COVID-19) pandemic has created more devastation among dialysis patients than among the general population. Patient-level prediction models for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are crucial for the early identification of patients to prevent and mitigate outbreaks within dialysis clinics. As the COVID-19 pandemic evolves, it is unclear whether or not previously built prediction models are still sufficiently effective. We developed a machine learning (XGBoost) model to predict during the incubation period a SARS-CoV-2 infection that is subsequently diagnosed after 3 or more days. We used data from multiple sources, including demographic, clinical, treatment, laboratory, and vaccination information from a national network of hemodialysis clinics, socioeconomic information from the Census Bureau, and county-level COVID-19 infection and mortality information from state and local health agencies. We created prediction models and evaluated their performances on a rolling basis to investigate the evolution of prediction power and risk factors. From April 2020 to August 2020, our machine learning model achieved an area under the receiver operating characteristic curve (AUROC) of 0.75, an improvement of over 0.07 from a previously developed machine learning model published by Kidney360 in 2021. As the pandemic evolved, the prediction performance deteriorated and fluctuated more, with the lowest AUROC of 0.6 in December 2021 and January 2022. Over the whole study period, that is, from April 2020 to February 2022, fixing the false-positive rate at 20%, our model was able to detect 40% of the positive patients. We found that features derived from local infection information reported by the Centers for Disease Control and Prevention (CDC) were the most important predictors, and vaccination status was a useful predictor as well. Whether or not a patient lives in a nursing home was an effective predictor before vaccination, but became less predictive after vaccination. As found in our study, the dynamics of the prediction model are frequently changing as the pandemic evolves. County-level infection information and vaccination information are crucial for the success of early COVID-19 prediction models. Our results show that the proposed model can effectively identify SARS-CoV-2 infections during the incubation period. Prospective studies are warranted to explore the application of such prediction models in daily clinical practice. 

A hybrid structural stress method is presented for significantly simplifying spot weld representations in fatigue evaluation of complex spot-welded structures while retaining a high degree of accuracy in structural stress computation. The method is formulated by extracting nodal forces and moments around a group of domain elements connected to a spot weld represented by a regular beam element. Through a systematic decomposition technique, existing closed-form solutions, previously only valid for modeling single-spot weld test specimens, can now be used for calculating the relevant structural stresses under complex loading conditions in structures, as validated its ability in correlating fatigue test data. 

Smoothing splines provide a powerful and flexible means for nonparametric estimation and inference. With a cubic time complexity, fitting smoothing spline models to large data is computationally prohibitive. In this paper, we use the theoretical optimal eigenspace to derive a low‐rank approximation of the smoothing spline estimates. We develop a method to approximate the eigensystem when it is unknown and derive error bounds for the approximate estimates. The proposed methods are easy to implement with existing software. Extensive simulations show that the new methods are accurate, fast and compare favourably against existing methods.

 

Nonparametric regression has been widely used to deal with nonlinearity and heteroscedasticity in financial time series. As the ratio of the mean and standard deviation functions, the Sharpe ratio function is one of the most commonly used risk/return measures in financial econometrics. Most existing methods take an indirect procedure, which first estimates the mean and variance functions and then applies these two functions to estimate the Sharpe ratio function. In practice, however, such an indirect procedure can often be less efficient. In this article, we propose a direct method to estimate the Sharpe ratio function by local linear regression. We further establish the asymptotic normality of the proposed estimator, apply Monte Carlo simulations to evaluate its finite sample performance, and compare it with the indirect method. The usefulness of our new method is also illustrated through a real data analysis.

 

Microarrays are one of the most widely used high throughput technologies. One of the main problems in the area is that conventional estimates of the variances that are required in the t-statistic and other statistics are unreliable owing to the small number of replications. Various methods have been proposed in the literature to overcome this lack of degrees of freedom problem. In this context, it is commonly observed that the variance increases proportionally with the intensity level, which has led many researchers to assume that the variance is a function of the mean. Here we concentrate on estimation of the variance as a function of an unknown mean in two models: the constant coefficient of variation model and the quadratic variance–mean model. Because the means are unknown and estimated with few degrees of freedom, naive methods that use the sample mean in place of the true mean are generally biased because of the errors-in-variables phenomenon. We propose three methods for overcoming this bias. The first two are variations on the theme of the so-called heteroscedastic simulation–extrapolation estimator, modified to estimate the variance function consistently. The third class of estimators is entirely different, being based on semiparametric information calculations. Simulations show the power of our methods and their lack of bias compared with the naive method that ignores the measurement error. The methodology is illustrated by using microarray data from leukaemia patients.